P355 Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)
ECCO'20 Vienna
2020
P356 Infectious events in patients with inflammatory bowel disease: The impact of immunomodulators and tumour necrosis factor antagonist therapy
ECCO'20 Vienna
2020
P358 Predictors of response to faecal microbiota transplantation in patients with active ulcerative colitis
ECCO'20 Vienna
2020
P359 Platelet-rich stroma injection (PRS) as a novel surgical treatment of refractory perianal fistulas in Crohn’s disease: A pilot study
ECCO'20 Vienna
2020
P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)
ECCO'20 Vienna
2020
P363 Moderate endurance and muscle training are safe to perform for patients with quiescent or mild active Crohn’s disease and increases their strength
ECCO'20 Vienna
2020
P364 New insights into the molecular mechanisms of thalidomide in paediatric inflammatory bowel disease patients
ECCO'20 Vienna
2020
P367 Real-life long-term effectiveness and treatment persistence of vedolizumab in a single tertiary care cohort of Crohn’s disease patients
ECCO'20 Vienna
2020
P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice
ECCO'20 Vienna
2020
P369 Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre
ECCO'20 Vienna
2020
P370 Endoscopic balloon dilatation in paediatric stricturing Crohn’s disease: A retrospective collaborative study of the paediatric IBD Porto group of ESPGHAN
ECCO'20 Vienna
2020
P371 Self-medication with analgesics in ulcerative colitis: Results of a patient survey
ECCO'20 Vienna
2020